Brief: Grand Pharmaceutical Says NDA For Group Treated For Demodex Blepharitis Accepted By Nmpa
16/12/2024 10:04
Dec 16 (Reuters) - Grand Pharmaceutical 0512.HK :
* NDA FOR GROUP TREATED FOR DEMODEX BLEPHARITIS HAS BEEN
ACCEPTED
BY NMPA CHINA
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement